Insilico, Lilly Ink $2.75B AI Drug Deal
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Insilico Medicine announced a commercialization deal with Eli Lilly on Sunday valued at $115 million upfront plus up to $2.75 billion in biobucks tied to regulatory and commercial milestones.
- Lilly gains rights to develop, manufacture, and commercialize several of Insilico's preclinical AI-discovered oral therapeutic candidates; the specific assets licensed were not disclosed.
- Insilico CEO Alex Zhavoronkov publicly praised Lilly as the "absolutely best partner" for the candidates and said the pharma giant is "better in AI than Insilico" while calling Lilly's tirzepatide "the best drug ever invented by humans."
- Zhavoronkov disclosed he is personally taking Lilly's tirzepatide (Mounjaro/Zepbound), saying "Mounjaro makes me so happy every day. I want to develop the next one."
- Insilico's pipeline page was recently updated to show that a candidate targeting GLP-1 has been out-licensed to an undisclosed partner — a disease area where Lilly is already a dominant player.
- The deal comes as pharma giants increasingly partner with AI-native drug discovery firms to bolster early-stage pipelines.
Why it matters: For Insilico, the $115 million upfront provides meaningful validation and runway at a moment when AI-drug-discovery companies are under pressure to show their platforms can produce commercially viable candidates. For Lilly, the deal extends its oral-therapeutics footprint and gives it access to Insilico's preclinical pipeline — including what appears to be a GLP-1 candidate, a category where Lilly already leads with tirzepatide.
Ask SkimNews
